Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
NCT ID NCT07737522
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial investigates whether semaglutide, a GLP-1 agonist, can shift how the heart produces energy in people with pulmonary arterial hypertension (PAH). The heart in PAH often relies on inefficient fuel sources, and the drug may help it switch to a more efficient form. Researchers will use a special MRI technique to measure changes in heart energy molecules. The study enrolls 32 adults with confirmed PAH who are already on stable PAH therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a GLP-1 agonist drug called semaglutide
- What this could lead to
- If it works, this could point toward a new treatment that helps the heart work more efficiently in people with pulmonary arterial hypertension.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply widely. The drug may not improve heart energy use or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests
- Could a new drug free PAH patients from daily pump therapy?